Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
Fast Forward

Sackler Family-Owned Purdue Pharma Files For Bankruptcy

(JTA) — The Sackler family-owned Purdue Pharma filed for bankruptcy as part of a tentative $12 billion settlement with dozens of state and local governments that filed lawsuits accusing the company of fueling and profiting from the opioid epidemic.

The company’s board met Sunday evening to approve the move, Reuters reported, and the bankruptcy was filed in White Plains, New York.

Twenty-four states and five U.S. territories, as well as 2,000 cities, counties and other plaintiffs, have sued the Connecticut-based company. Two dozen other states have not committed to the settlement and are being encouraged to do so, according to Reuters.

The prescription painkiller OxyContin, introduced by Purdue in 1996, helped make the Sacklers America’s 19th richest family with a combined net worth of $13 billion, according to Forbes. The company has been accused of aggressively marketing the powerful and addictive painkiller even as it became clear that the drugs were not as safe as advertised.

The bankruptcy filing will turn the private company into a “public beneficiary trust,” allowing the profits from all drug sales, including OxyContin, to go to the plaintiffs in the lawsuits.

The company also would agree to give its addiction treatment drugs free to the public. Those drugs are currently under development.

The Sacklers, who are Jewish, would cede control of Purdue in the proposed settlement. They have offered $3 billion in cash and at least another $1.5 billion from the proposed sale of another company they own, called Mundipharma, Reuters reported, citing the company.

“It is our hope the bankruptcy reorganization process that is now underway will end our ownership of Purdue and ensure its assets are dedicated for the public benefit,” the family said in a statement.

The reorganization and settlement will require approval by a U.S. bankruptcy judge.

The Sackler family has supported Tel Aviv University’s School of Medicine and the Jewish Museum in Berlin among its philanthropic endeavors.

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.

Now more than ever, American Jews need independent news they can trust, with reporting driven by truth, not ideology. We serve you, not any ideological agenda.

At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and the protests on college campuses.

Readers like you make it all possible. Support our work by becoming a Forward Member and connect with our journalism and your community.

Make a gift of any size and become a Forward member today. You’ll support our mission to tell the American Jewish story fully and fairly. 

— Rachel Fishman Feddersen, Publisher and CEO

Join our mission to tell the Jewish story fully and fairly.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.